Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: A population-based case-control study in China

Cancer Research

Volumn 60, Issue 18, 2000, Pages 5111-5116

  Hsing, A W ^a   Gao, Y T ^a   Wu, G ^a   Wang, X ^a   Deng, J ^a   Chen, Y L ^a   Sesterhenn, I A ^a   Kash Mostofi, F ^a   Benichou, J ^a   Chang, C ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER RISK; CASE CONTROL STUDY; CHINA; CONTROLLED STUDY; GENETIC POLYMORPHISM; GENETIC RISK; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RECEPTOR GENE; TRINUCLEOTIDE REPEAT;

AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHINA; DNA, NEOPLASM; HUMAN; MALE; MIDDLE AGE; PEPTIDES; POLYMORPHISM (GENETICS); PROSTATIC NEOPLASMS; RECEPTORS, ANDROGEN; REPETITIVE SEQUENCES, NUCLEIC ACID; RISK FACTORS;

EID: 0034665359     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (42)

1. International trends and patterns of prostate cancer incidence and mortality
2. Rising incidence of prostate cancer in Shanghai, China
3. Possible underestimation of the incidence rate of prostate cancer in Japan
4. Latent carcinoma of the prostate of autopsy in seven areas
5. Regulation of androgen action
6. The androgen receptor in prostate cancer
7. Molecular defects of the androgen receptor
8. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function
9. Reduced androgen receptor gene expression with first exon CAG repeat expansion
10. Long polyglutamine tracts in the androgen receptor are associated with reduced transactivation, impaired sperm production, and male infertility
11. Spermatogenesis: Its regulation by testosterone and FSH
12. Androgen receptor mutation in Kennedy's disease
13. Spinal and bulbar muscular atrophy: A trinucleotide-repeat expansion neurodegenerative disease
14. Evidence for a repressive function of the long polyglutamine tract in the human androgen receptor: Possible pathogenetic relevance for the (CAG)n-expanded neuronopathies
15. Transcriptional activation and transient expression of the human androgen receptor
16. Polymorphic repeats in the androgen receptor gene: Molecular markers of prostate cancer risk
17. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer
18. A Association of prostate cancer risk with genetic polymorphisms in vitamin D receptor and androgen receptor
19. The androgen receptor gene GGN microsatellite and prostate cancer risk
20. The androgen receptor CAG repeat polymorphism and its relationship to prostate cancer
21. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer
22. Androgen receptor gene CAG repeat length varies in a race-specific fashion in men without prostate cancer
23. Androgen receptor CAG repeat lengths in prostate cancer: Correlation with age of onset
24. CAG repeat length in the androgen receptor gene is related to age at prostate cancer diagnosis and response to endocrine therapy, but not to risk of prostate cancer
25. The CAG and GGC microsatellites of the androgen receptor gene are in linkage disequilibrium in men with prostate cancer
26. Genetic variation at five trimeric and tetrarneric tandem repeat loci in four human population groups
27. (CAG)nCAA, and GGN repeats in the human androgen receptor gene are not associated with prostate cancer in a French-German population
28. Androgen receptor gene mutations in hormone-refractory prostate cancer
29. Amplification of the androgen receptor gene is associated with P53 mutation in hormone-refractory recurrent prostate cancer
30. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone
31. Microsatellite mutation (CAG24→18) in the androgen receptor gene in human prostate cancer
32. The role of the androgen receptor in the development and progression of prostate cancer
33. Androgen receptor gene amplification: A possible molecular mechanism for androgen deprivation therapy failure in prostate cancer
34. Activation of the androgen receptor by polypeptide growth factors and cellular regulators
35. Estrogen, but not androgens, regulates androgen receptor messenger ribonucleic acid expression in the developing male rat forebrain
36. Modulation of androgen receptor (AR)-mediated transcriptional activity by EGF in the developing mouse reproductive tract primary cells
37. The androgen receptor: Genetic considerations in the development and treatment of prostate cancer
38. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells
39. From estrogen to androgen receptor: A new pathway for sex hormones in prostate
40. AIBI, a steroid receptor coactivator amplified in breast and ovarian cancer